TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Profitability
This table compares TScan Therapeutics and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TScan Therapeutics | -855.84% | -59.83% | -35.42% |
| ProKidney | N/A | N/A | -8.80% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for TScan Therapeutics and ProKidney, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TScan Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
| ProKidney | 0 | 3 | 2 | 0 | 2.40 |
Insider and Institutional Ownership
82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares TScan Therapeutics and ProKidney”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TScan Therapeutics | $12.20 million | 22.40 | -$89.22 million | ($1.28) | -4.04 |
| ProKidney | N/A | N/A | -$35.47 million | ($0.57) | -3.22 |
ProKidney has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
TScan Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Summary
ProKidney beats TScan Therapeutics on 9 of the 13 factors compared between the two stocks.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
